Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII), accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing fibrin clot formation.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Intravenous: Initial bolus of 5,000 units followed by continuous infusion of 13-21 units/kg/hour (typically 1,000-2,000 units/hour) titrated to aPTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours for prophylaxis; 10,000-20,000 units every 12 hours for treatment.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (dose-dependent, saturable clearance); prolonged to 2-6 hours in renal impairment, obese patients, or with high doses; clinical anticoagulant effect may persist 2-4 hours after a single IV bolus.
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Primarily renal (via reticuloendothelial system); 40-50% excreted unchanged in urine; 20-30% metabolized to uroheparin and excreted renally; minor biliary (<5%).
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Category A/B
Category C
Electrolyte
Electrolyte